XOMA (XOMA) Competitors $20.53 -0.27 (-1.30%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. GERN, MYGN, ZBIO, RIGL, VSTM, VNDA, EBS, IRWD, CDXS, and SGMOShould you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Geron (GERN), Myriad Genetics (MYGN), Zenas Biopharma (ZBIO), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Ironwood Pharmaceuticals (IRWD), Codexis (CDXS), and Sangamo Therapeutics (SGMO). These companies are all part of the "biotechnology" industry. XOMA vs. Geron Myriad Genetics Zenas Biopharma Rigel Pharmaceuticals Verastem Vanda Pharmaceuticals Emergent BioSolutions Ironwood Pharmaceuticals Codexis Sangamo Therapeutics XOMA (NASDAQ:XOMA) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk. Do analysts prefer XOMA or GERN? XOMA presently has a consensus price target of $72.00, indicating a potential upside of 250.71%. Geron has a consensus price target of $5.75, indicating a potential upside of 363.71%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than XOMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Geron 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Does the media prefer XOMA or GERN? In the previous week, Geron had 28 more articles in the media than XOMA. MarketBeat recorded 36 mentions for Geron and 8 mentions for XOMA. XOMA's average media sentiment score of 0.95 beat Geron's score of 0.05 indicating that XOMA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 3 Very Positive mention(s) 3 Positive mention(s) 22 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral Does the MarketBeat Community believe in XOMA or GERN? Geron received 59 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 70.03% of users gave Geron an outperform vote while only 65.53% of users gave XOMA an outperform vote. CompanyUnderperformOutperformXOMAOutperform Votes44165.53% Underperform Votes23234.47% GeronOutperform Votes50070.03% Underperform Votes21429.97% Is XOMA or GERN more profitable? XOMA has a net margin of -151.34% compared to Geron's net margin of -682.48%. XOMA's return on equity of -24.95% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets XOMA-151.34% -24.95% -9.64% Geron -682.48%-67.53%-45.46% Which has more volatility and risk, XOMA or GERN? XOMA has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Geron has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Which has preferable earnings and valuation, XOMA or GERN? XOMA has higher earnings, but lower revenue than Geron. XOMA is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA$10.22M24.01-$40.83M-$2.07-9.92Geron$76.99M10.26-$184.13M-$0.27-4.59 Do institutionals & insiders believe in XOMA or GERN? 95.9% of XOMA shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 7.2% of XOMA shares are held by insiders. Comparatively, 3.1% of Geron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryXOMA beats Geron on 10 of the 19 factors compared between the two stocks. Remove Ads Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$245.40M$6.25B$5.28B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-5.906.6921.6317.68Price / Sales24.01222.70371.0892.88Price / CashN/A65.6738.1534.64Price / Book2.665.776.373.94Net Income-$40.83M$142.01M$3.20B$247.45M7 Day Performance1.68%2.88%1.79%0.48%1 Month Performance0.49%-13.93%-9.41%-7.08%1 Year Performance-15.79%-12.36%9.61%-0.35% XOMA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA4.4434 of 5 stars$20.53-1.3%$72.00+250.7%-14.5%$245.40M$10.22M-5.9010GERNGeron3.7569 of 5 stars$1.41+2.2%$5.75+307.8%-63.8%$898.04M$76.99M-4.4170Short Interest ↑MYGNMyriad Genetics3.8068 of 5 stars$8.07-0.7%$20.89+158.9%-58.2%$736.86M$837.60M-6.212,700ZBIOZenas BiopharmaN/A$7.75+0.5%$40.00+416.1%N/A$323.94M$5M-2.18N/AGap DownHigh Trading VolumeRIGLRigel Pharmaceuticals2.769 of 5 stars$17.04-1.2%$36.80+116.0%+48.2%$304.39M$179.28M121.72160News CoverageGap DownVSTMVerastem3.0561 of 5 stars$5.10-1.2%$13.88+172.1%-56.5%$262.58M$10M-1.6050VNDAVanda Pharmaceuticals4.1855 of 5 stars$4.19+1.2%$16.50+293.8%+7.6%$244.34M$198.77M-13.09290News CoverageGap DownEBSEmergent BioSolutions4.3047 of 5 stars$4.43-1.9%$14.33+223.3%+134.1%$240.88M$1.01B-1.082,420Positive NewsIRWDIronwood Pharmaceuticals4.5689 of 5 stars$1.27-5.2%$8.60+577.2%-90.7%$203.24M$351.41M-42.33220Analyst DowngradeShort Interest ↓Analyst RevisionNews CoverageGap DownCDXSCodexis3.1253 of 5 stars$2.06-3.3%$8.33+304.5%-16.4%$170.64M$59.35M-2.37250Gap DownSGMOSangamo Therapeutics2.1807 of 5 stars$0.71+7.7%$5.17+630.9%+33.0%$158.85M$57.80M-0.94480Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Geron Alternatives Myriad Genetics Alternatives Zenas Biopharma Alternatives Rigel Pharmaceuticals Alternatives Verastem Alternatives Vanda Pharmaceuticals Alternatives Emergent BioSolutions Alternatives Ironwood Pharmaceuticals Alternatives Codexis Alternatives Sangamo Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
